Drug Profile
Bremelanotide - Cosette Pharmaceuticals
Alternative Names: PT-141; Rekynda™; VyleesiLatest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator University of Arizona
- Developer AMAG Pharmaceuticals; Cosette Pharmaceuticals; Kwang Dong Pharmaceutical; Palatin Technologies; Shanghai Fosun Pharmaceutical
- Class Cyclic peptides; Erectile dysfunction therapies; Hypothalamic hormones; Melanocyte-stimulating hormones
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Female sexual dysfunction
Highest Development Phases
- Marketed Female sexual dysfunction
- Phase II Diabetic nephropathies
- Preclinical Obesity
- Discontinued Erectile dysfunction; Haemorrhagic shock; Vascular disorders
Most Recent Events
- 15 Feb 2024 Palatin Technologies plans to initiate IND enabling activities for Bremelanotid in Obesity in the second half of 2024
- 15 Feb 2024 Palatin Technologies plans a phase II trial for Obesity (Combination therapy) in the first half of 2024
- 15 Feb 2024 Palatin Technologies plans a phase II trial for Erectile dysfunction (Treatment experience) in the first half of 2024